Institutional Investors Have a Lot Riding on Nektar Therapeutics (NASDAQ:NKTR) With 68% Ownership
Insider Sale: Chief Legal Officer of $NKTR (NKTR) Sells 33,402 Shares
Don't Ignore The Insider Selling In Nektar Therapeutics
Promising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment With Rezpegaldesleukin
Express News | Nektar Therapeutics : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $6.5
Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group...
